Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor

Por Pradhan, Anuradha, Lambert, Que T., Reuther, Gary W.
Publicado em 2007

Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors

Por Pradhan, Anuradha, Lambert, Que T., Griner, Lori N., Reuther, Gary W.
Publicado em 2010

Mutations in the Transmembrane and Juxtamembrane Domains Enhance IL27R Transforming Activity

Por Lambert, Que T., Pradhan, Anuradha, Roll, J. Devon, Reuther, Gary W.
Publicado em 2011

Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia

Por Reuther, Gary W., Lambert, Que T., Caligiuri, Michael A., Der, Channing J.
Publicado em 2000

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

Por Gordon, Geoff M., Lambert, Que T., Daniel, Kenyon G., Reuther, Gary W.
Publicado no Biochem J (2010)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN...

Por Mazzacurati, Lucia, Lambert, Que T., Pradhan, Anuradha, Griner, Lori N., Huszar, Dennis, Reuther, Gary W.
Publicado no Oncotarget (2015)

Oncogenic Ras Blocks Anoikis by Activation of a Novel Effector Pathway Independent of Phosphatidylinositol 3-Kinase

Por McFall, Aidan, Ülkü, Aylin, Lambert, Que T., Kusa, Andrea, Rogers-Graham, Kelley, Der, Channing J.
Publicado em 2001

Interferon Regulatory Factor 7 Is Associated with Epstein-Barr Virus-Transformed Central Nervous System Lymphoma and Has Oncogenic Properties

Por Zhang, Luwen, Zhang, Jun, Lambert, Que, Der, Channing J., Del Valle, Luis, Miklossy, Judith, Khalili, Kamel, Zhou, You, Pagano, Joseph S.
Publicado em 2004

Dependence of Dbl and Dbs Transformation on MEK and NF-κB Activation

Por Whitehead, Ian P., Lambert, Que T., Glaven, Judith A., Abe, Karon, Rossman, Kent L., Mahon, Gwendolyn M., Trzaskos, James M., Kay, Robert, Campbell, Sharon L., Der, Channing J.
Publicado em 1999

Potent dual BET bromodomain-kinase inhibitors as value added multi-targeted chemical probes and cancer therapeutics

Por Ember, Stuart W., Lambert, Que T., Berndt, Norbert, Gunawan, Steven, Ayaz, Muhammad, Tauro, Marilena, Zhu, Jin-Yi, Cranfill, Paula J., Greninger, Patricia, Lynch, Conor C., Benes, Cyril H., Lawrence, Harshani R., Reuther, Gary W., Lawrence, Nicholas J., Schönbrunn, Ernst
Publicado no Mol Cancer Ther (2017)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

Por Koblish, Holly, Li, Yun-long, Shin, Niu, Hall, Leslie, Wang, Qian, Wang, Kathy, Covington, Maryanne, Marando, Cindy, Bowman, Kevin, Boer, Jason, Burke, Krista, Wynn, Richard, Margulis, Alex, Reuther, Gary W., Lambert, Que T., Dostalik Roman, Valerie, Zhang, Ke, Feng, Hao, Xue, Chu-Biao, Diamond, Sharon, Hollis, Greg, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Vaddi, Kris, Scherle, Peggy
Publicado no PLoS One (2018)